Evidence map›Paper›PMID 35721857›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Polyvinylpyrrolidone-Modified Taxifolin Liposomes Promote Liver Repair by Modulating Autophagy to Inhibit Activation of the TLR4/NF-κB Signaling Pathway.

Qiteng Ding, Wencong Liu, Xinglong Liu, Chuanbo Ding, Yingchun Zhao, Ling Dong, Huiying Chen, Shuwen Sun, Yiwen Zhang, Jinping Zhang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Qiteng DingCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Wencong LiuCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Xinglong LiuCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Chuanbo DingCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Yingchun ZhaoCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Ling DongCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Huiying ChenCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Shuwen SunCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Yiwen ZhangCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Jinping ZhangCollege of Chinese Medicinal Materials, Jilin Agricultural University, Jilin, China.
Ming WuCollege of Life Science, Jilin Agricultural University, Jilin, China.
Jilin Agricultural University · CNJilin Agricultural Science and Technology University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Taxifolin (TAX) is a hepatoprotective flavanol compound, which is severely limited by poor solubility and low bioavailability. Liposomes (Lips) are used as well-recognized drug carrier systems that improve the water solubility and bioavailability of drugs, but are easily damaged by gastric juice after oral administration, resulting in the release of drugs in the gastric juice. Therefore, it is important to find materials that modify liposomes and avoid the destruction of the liposomal phospholipid bilayer structure by the gastrointestinal environment. Taxifolin liposomes (TAX-Lips) were modified by polyvinylpyrrolidone-k30 (PVP-TAX-Lips) and manufactured using a thin-film hydration technique. Particle size (109.27 ± 0.50 nm), zeta potential (-51.12 ± 3.79 mV), polydispersity coefficient (PDI) (0.189 ± 0.007), and EE (84.7 ± 0.2%) of PVP-TAX-Lips were studied. In addition, the results of

Indexed as

acute liver injuryautophagyliposomespolyvinylpyrrolidone-K30taxifolinTLR4/NF-κB

Identifiers

PMID35721857
PMCPMC9199375
OpenAlexW4283398081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.